Immatics Reports Full Year 2025 Results, Reaffirms Anzu-cel Phase 3 Timelines, and Expands Moderna Collaboration

summarizeSummary

Immatics N.V. announced full year 2025 financial results, reporting an increased net loss but reaffirming critical Phase 3 timelines for its lead asset, anzu-cel, and detailing progress across its PRAME pipeline, alongside an expanded collaboration with Moderna.

check_boxKey Events

• Full Year 2025 Financial Results

  The company reported a net loss of $230.8 million for full year 2025, compared to a net profit of $17.9 million in 2024, primarily due to increased R&D expenses. Revenue decreased to $56.8 million from $183.1 million in 2024.

• Anzu-cel Phase 3 Progress and Timelines Reaffirmed

  The global, randomized, controlled Phase 3 SUPRAME trial for anzu-cel (IMA203) in advanced melanoma is ongoing. Interim and final analyses are expected to be triggered in 2026, with BLA submission in 1H 2027 and commercial launch in 2H 2027, as planned.

• Moderna Collaboration Expanded with Milestone Payment

  The TCER® collaboration with Moderna was expanded, triggering a $5 million milestone payment to Immatics in January 2026. The first mRNA-based TCER® product candidate is planned to advance into clinical development, with Immatics conducting the Phase 1 trial fully reimbursed by Moderna.

• Extended Cash Runway

  Cash and cash equivalents totaled $551.4 million as of December 31, 2025, following a $125 million public offering completed in December 2025. This extends the company's cash reach into 2028.

auto_awesomeAnalysis

Immatics N.V. reported a significant net loss for full year 2025, driven by increased R&D expenses as it advances its clinical pipeline. However, the company provided crucial updates on its PRAME franchise, notably reaffirming the Phase 3 SUPRAME trial timelines for its lead asset, anzu-cel, with BLA submission expected in 1H 2027 and commercial launch in 2H 2027. This reiteration of the path to market for a key therapeutic candidate is a strong positive signal for a clinical-stage biotech. Furthermore, the expansion of the collaboration with Moderna and a $5 million milestone payment underscore continued strategic partnerships and pipeline development. The company's cash position, bolstered by a recent public offering, extends its runway into 2028, providing financial stability to execute on its clinical goals.